Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.49 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27877978 | 0.92 | SMN1; SMN2 (0.51) | SMN1; SMN2ALOX15TSHRCYP2C19HIF1A | |
| SCHEMBL6546027 | 0.90 | POLB (0.61) | SMN1; SMN2ALOX15TDP1ALDH1A1LMNA | |
| SCHEMBL30323772 | 0.90 | POLB (0.61) | SMN1; SMN2ALOX15TDP1ALDH1A1LMNA | |
| SCHEMBL7223947 | 0.85 | SMN1; SMN2 (0.49) | SMN1; SMN2ALOX15TSHRCYP2C19HIF1A | |
| SCHEMBL28264607 | 0.85 | ALOX15 (0.55) | ALOX15TSHRCYP2C19HIF1ATDP1 | |
| SCHEMBL10668835 | 0.84 | SMN1; SMN2 (0.48) | SMN1; SMN2ALOX15TSHRCYP2C19HIF1A | |
| SCHEMBL10588657 | 0.84 | ALOX15 (0.62) | ALOX15TSHRCYP2C19HIF1ATDP1 | |
| SCHEMBL10891813 | 0.83 | SMN1; SMN2 (0.61) | SMN1; SMN2ALOX15TSHRCYP2C19HIF1A | |
| SCHEMBL21820780 | 0.82 | CYP2C19 (0.60) | ALOX15TSHRCYP2C19HIF1ATDP1 | |
| SCHEMBL23388356 | 0.81 | CYP2C19 (0.58) | ALOX15TSHRCYP2C19HIF1ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110862308-A | Preparation method and application of formaldehyde alcohol solution | 湖北泰盛化工有限公司 | 2020-03-06 | — | — | CN | claimed |
| CN-1391439-A | Synergistic herbicidal active substance combinations | BAYER AG (DE) | 2003-01-15 | — | — | CN | claimed |
| CN-1378424-A | Selective herbicides on basis of n-aryl-trizoline (thio) ones | BAYER AG (DE) | 2002-11-06 | — | — | CN | claimed |
| CN-110612119-B | Phosphatidylether (PLE) CAR T cell tumor targeting (CTCT) agents | 西雅图儿童医院（DBA西雅图儿童研究所） | 2024-10-29 | — | — | CN | disclosed |
| US-20240226160-A9 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240131072-A1 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) | 2024-04-25 | — | — | US | disclosed |
| EP-4291571-A2 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | Seattle Children's Hospital d/b/a Seattle Children's Research Institute (US) | 2023-12-20 | — | — | EP | disclosed |
| US-20230322925-A1 | PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS | SEATTLE CHILDREN’S HOSPITAL DBA SEATTLE CHILDREN’S RES INSTITUTE (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230172981-A1 | METHODS AND COMPOSITIONS FOR STIMULATION OF CHIMERIC ANTIGEN RECEPTOR T CELLS WITH HAPTEN LABELLED CELLS | SEATTLE CHILDRENS HOSPITAL DBA SEATTLE CHILDRENS RES INST (US) | 2023-06-08 | — | — | US | disclosed |
| US-11649288-B2 | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents | SEATTLE CHILDREN'S HOSPITAL (US) | 2023-05-16 | — | — | US | disclosed |
| CN-114920418-A | Resource recovery method for amide pesticide production wastewater and application thereof | 南通江山农药化工股份有限公司 | 2022-08-19 | — | — | CN | disclosed |
| US-4371717-A | ETHERIFICATION, ALDEHYDES | MONSANTO COMPANY (US) | 1983-02-01 | — | — | US | disclosed |
| EP-0066106-A1 | New phenoxybenzoates, process for preparing these compounds, compositions containing them and method of use | GAF CORPORATION (US) | 1982-12-08 | — | — | EP | disclosed |
| US-4319917-A | N-(2-Cyanoalkoxy)methyl-N-(2-,3-, or 6-alkylphenyl)-α-haloacetamides | PPG INDUSTRIES, INC. (US) | 1982-03-16 | — | — | US | disclosed |
| EP-0037656-A1 | A process for the in-solvent, in-situ generation of N-substituted-2-haloacetanilides | MONSANTO COMPANY (US) | 1981-10-14 | — | — | EP | disclosed |
| US-4284564-A | Process for the in-solvent, in-situ generation of haloalkyl alkyl ethers useful to produce N-substituted-2-haloacetanilides | MONSANTO COMPANY (US) | 1981-08-18 | — | — | US | disclosed |
| US-4258196-A | REACTING THE ANION OF A PRIMARY OR SECONDARY 2-HALOACETAMIDE WITH AN ALKYLATING AGENT | MONSANTO COMPANY (US) | 1981-03-24 | — | — | US | disclosed |
| US-4237068-A | Primary aminoacylanilides | ASTRA PHARMACEUTICAL PRODUCTS, INC. (US) | 1980-12-02 | — | — | US | disclosed |
| US-4218477-A | LONG LASTING ORAL AGENTS | ASTRA PHARMACEUTICAL PRODUCTS, INC. (US) | 1980-08-19 | — | — | US | disclosed |
| US-4178383-A | Fungicidally active oxime-ethers of isonitrosocyanoacetamides | BAYER AKTIENGESELLSCHAFT (DE) | 1979-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11649288-B2 | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents | PHOSPHO1, LCAT, CD47 | SMN1; SMN2 1861/4885ALOX15 700/4885TSHR 1224/4885 |
| US-20230322925-A1 | PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS | PHOSPHO1, LCAT, CD47 | SMN1; SMN2 1861/4885ALOX15 700/4885TSHR 1224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.